Method Of Regulating Cell Metabolism Or Physiology Patents (Class 435/375)
  • Patent number: 11322225
    Abstract: The present disclosure provides systems and methods for determining effects of genetic variants on selection of polyadenylation sites (PAS) during polyadenylation processes. In an aspect, the present disclosure provides a polyadenylation code, a computational model that can predict alternative polyadenylation patterns from transcript sequences. A score can be calculated that describes or corresponds to the strength of a PAS, or the efficiency in which it is recognized by the 3?-end processing machinery. The polyadenylation model may be used, for example, to assess the effects of anti-sense oligonucleotides to alter transcript abundance. As another example, the polyadenylation model may be used to scan the 3?-UTR of a human genome to find potential PAS.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: May 3, 2022
    Assignee: Deep Genomics Incorporated
    Inventors: Brendan Frey, Michael Ka Kit Leung
  • Patent number: 11293008
    Abstract: A method of growing primary human epithelial cells, in particular human epithelial cells using a basal formula containing individual (a) amino acids, (b) vitamins, (c) trace elements, and (d) other organics such as linoleic acid. The basal medium may be a mixture of amino acids, vitamins, and salts that constitute the basic media that is used to culture epithelial cells over a number of population doublings, e.g., over at least one week, while maintaining a normal phenotype and exerting low stress on the cultured cells, and maintaining lineage heterogeneity.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 5, 2022
    Assignee: The Regents of the University of California
    Inventors: Mark A. LaBarge, Martha R. Stampfer, James C. Garbe
  • Patent number: 11293004
    Abstract: A bench top incubator is described. The bench top incubator includes a multiple temperature sensors and control systems so as to provide independent data logs of temperature data from each of the multiple temperature sensors. The incubator is relatively simple and small in design and can be conveniently located to carry out temperature processing of biological samples such as fixed cells and tissues, biological fluids, and so forth.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 5, 2022
    Assignee: SciTech Consultants, LLC
    Inventor: Anuradha Murali
  • Patent number: 11261443
    Abstract: This invention provides a method for the in vivo delivery of oligonucleotides. The invention utilizes the presence of one or plurality of HES linked to an oligonucleotide to deliver a nucleic acid sequence of interest into the cytoplasm of cells and tissues of live organisms. The delivery vehicle is nontoxic to cells and organisms. Since delivery is sequence-independent and crosses membranes in a receptor-independent manner, the delivered oligonucleotide can target complementary sequences in the cytoplasm as well as in the nucleus of live cells. Sequences of bacterial or viral origin can also be targeted. The method can be used for delivery of genes coding for expression of specific proteins, antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs or any nucleic acid sequence in a living organism. The latter include mammals, plants, and microorganisms such as bacteria, protozoa, and viruses.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 1, 2022
    Assignee: ONCOIMMUNIN INC.
    Inventors: Beverly Packard, Akira Komoriya
  • Patent number: 11246906
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 15, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
  • Patent number: 11235317
    Abstract: A collection pipette that collects a microscopic object includes a first tube part, a second tube part connected to an end of the first tube part, and a third tube part connected to the other end of the first tube part. The longitudinal direction of the third tube part intersects with the longitudinal direction of the first tube part, and is parallel to the longitudinal direction of the second tube part. For example, the length in the longitudinal direction of the third tube part is shorter than the length in the longitudinal direction of the first tube part.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 1, 2022
    Assignee: NSK LTD.
    Inventors: Nobuaki Tanaka, Sumio Sugita, Richard House
  • Patent number: 11219634
    Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 11, 2022
    Assignee: Genevant Sciences GmbH
    Inventors: Mary G. Prieve, Michael E. Houston, Jr., Pierrot Harvie, Sean D. Monahan
  • Patent number: 11198869
    Abstract: Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5?-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: December 14, 2021
    Assignee: The Texas A&M University System
    Inventor: Scott Victor Dindot
  • Patent number: 11155785
    Abstract: The present invention provides a hollow fiber membrane module which makes it possible to concentrate incubated platelets by efficiently removing water from an incubated platelet suspension liquid containing incubated platelets while suppressing deterioration of the function of the incubated platelets. The present invention provides an incubated platelet concentration module in which a plurality of hollow fiber membranes each having pores with an average pore diameter of 2 ?m or less on a surface of the hollow fiber membrane are packed in a casing having at least one inlet for supplying an incubated platelet suspension liquid before concentration into the hollow fiber membranes, wherein a value (X/Y1) obtained by dividing a total cross-sectional area (X) of the plurality of hollow fiber membranes by a total cross-sectional area (Y1) of the least one inlet is 4.0 or less.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: October 26, 2021
    Inventors: Kenichi Harimoto, Hirokazu Sakaguchi, Kota Hatta, Kazuhiro Tanahashi
  • Patent number: 11154470
    Abstract: The present invention relates to the field of dental care, e.g., with toothpaste, tooth gel, mouth-wash, mouth spray or oral care foam. In particular, it provides an anti-inflammatory and senolytic dental care product with tooth whitening characteristics. The dental care product comprises calcium phosphate particles of a specific size, the self-assembling peptide P11-4 or oligopeptide 104 of SEQ ID NO: 1, an extract of a plant of the genus Rhododendron, preferably, an alpine rose or Alpenrose such as Rhododendron ferrugineum or Rhododendron hirsutum, and an extract of a plant of the genus Leontopodium, such as Leontopodium nivale, which is also called Edelweiss. The dental care product may further comprise an extract of a plant of the genus Eleutherococcus, such as Eleutherococcus senticosus, which is also designated Siberian ginseng or Acanthopanax senticosus.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: October 26, 2021
    Assignee: vVardis AG
    Inventors: Michael Hug, Haleh Abivardi Brönner, Golnar Abivardi Signer, Dominikus Amadeus Lysek
  • Patent number: 11155576
    Abstract: Disclosed are peptides that contain up to about 35 amino acids, including a plurality of aromatic amino acid residues and either (i) an amino acid residue that is phosphorylated or sulfated, or (ii) an amino acid comprising an ester-moiety linked via peptide bond, or both (i) and (ii), wherein the peptide is capable of self-assembly to form nanofibrils in the presence of an enzyme that hydrolyzes the phosphate group, the sulfate group, or the ester-moiety. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels/nanofibrils upon exposure to target cells that secrete or express a surface bound ectoenzyme having hydrolase activity suitable to induce peptide gelation. These materials, and compositions containing the same, can be used for in vitro and in vivo cellular imaging, treating cancerous conditions, collecting a secretome from a cell upon which the pericellular hydrogels/nanofibrils form, and screening the collected secretome.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: October 26, 2021
    Assignee: BRANDEIS UNIVERSITY
    Inventors: Bing Xu, Junfeng Shi, Yi Kuang
  • Patent number: 11136584
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 5, 2021
    Assignee: Duke University
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie Lacroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Patent number: 11129923
    Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: September 28, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Lola M. Reid, Wencheng Zhang, Eliane Wauthier
  • Patent number: 11104900
    Abstract: An antisense oligonucleotide capable of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA, and methods for preventing or reducing exon 80 inclusion into a human COL7A1 mRNA.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: August 31, 2021
    Assignee: Wings Therapeutics, Inc.
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Gerardus Johannes Platenburg
  • Patent number: 11058644
    Abstract: Provided are a unimolecular nanoparticle, a composition thereof, and methods of use thereof, and includes 1) a dendritic polymer having a molecular weight of about 500-120,000 Da and terminating in hydroxyl, amino or carboxylic acid groups; 2) cationic polymers attached to at least a majority of the terminating groups of the dendritic polymer via a pH-sensitive linker, wherein each cationic polymer comprises a polymeric backbone attached to cationic functional groups and to weakly basic groups by disulfide bonds, wherein the molar ratio of cationic functional groups to weakly basic groups ranges from 1:1-5:1, and has a molecular weight from about 1,000-5,000 Da; and 3) poly(ethylene glycol) attached to a plurality of cationic polymers and having a terminal group selected from a targeting ligand, OH, O-alkyl, NH2, biotin, or a dye, wherein the terminal group of at least one poly(ethylene glycol) is having a molecular weight of about 1,000-15,000 Da.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 13, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Shaoqin Gong, Guojun Chen
  • Patent number: 11053500
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 6, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 11021707
    Abstract: The present disclosure relates to RNAi constructs with improved cellular uptake characteristics and methods of use of these compounds for silencing expression of long coding RNAs (IncRNAs).
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: June 1, 2021
    Assignees: Phio Pharmaceuticals Corp., Biogazelle NV
    Inventors: James Cardia, Karen G. Bulock, Joke Hedwig Vandesompele, Gert Van Peer
  • Patent number: 11015225
    Abstract: The invention relates to new identified mutations in the epidermal growth factor receptor gene, leading to amino acidic changes which highly correlate with the resistance to a therapy regimen comprising cetuximab. The invention includes peptide sequences and primers to detect the mutations, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: May 25, 2021
    Assignees: FUNDACIÓ INSTITUT MAR D'INVESTIGACIONS MEDIQUES (IMIM)
    Inventors: Alberto Bardelli, Sabrina Arena, Clara Montagut Viladot, Joan Albanell Mestres, Ana Rovira Guerin, Beatriz Bellosillo Paricio, Alba Dalmases Massegú
  • Patent number: 11015169
    Abstract: An object of the present invention is to provide a medium that comprises fewer protein components and enables the maintenance of pluripotent stem cells in an undifferentiated state. The culture medium for pluripotent stem cells comprises a GSK3? inhibitor (A) and a DYRK inhibitor (B).
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: May 25, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Kouichi Hasegawa, Shinya Yasuda, Hosein Shahsavarani, Noriko Yoshida
  • Patent number: 11008579
    Abstract: Method for targeted alteration of a duplex acceptor DNA sequence in a plant cell protoplast, comprising combining the duplex acceptor DNA sequence with a donor mutagenic nucleobase, wherein the duplex acceptor DNA sequence contains a first DNA sequence and a second DNA sequence which is the complement of the first DNA sequence and wherein the donor mutagenic nucleobase comprises at least one mismatch with respect to the duplex acceptor DNA sequence to be altered, preferably with respect to the first DNA sequence, wherein the method further comprises a step of introducing the donor mutagenic nucleobase into the cell protoplasts using polyethylene glycol (PEG) mediated transformation and the use of PEG protoplast transformation for enhancing the rate of targeted mutagenesis.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 18, 2021
    Assignee: Keygene N.V.
    Inventors: Paul Bundock, Michiel Theodoor Jan De Both, Frank Lhuissier
  • Patent number: 10953015
    Abstract: The present invention relates to a method of inhibiting p-glycoprotein (P-gp) expression in a cell. The method involves contacting a cell expressing P-gp with a composition comprising an effective amount of an A2A adenosine receptor (A2A AR) agonist to inhibit P-gp expression in the cell. Methods of enhancing the bioavailability of a chemotherapeutic in a subject having multi-drug resistant (MDR) cancer and methods of increasing P-gp-mediated efflux in a cell are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventor: Margaret Bynoe
  • Patent number: 10940239
    Abstract: Provided herein is a method of making an aligned ECM scaffold useful in refractive correction of the eye and repair of the cornea. Methods of use of the scaffold as well as a scaffold construct are provided.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yiqin Du, James L. Funderburgh, William R. Wagner, Jian Wu
  • Patent number: 10934527
    Abstract: Method for reprogramming differentiated cells into lineage restricted progenitor cells is provided. The method may include contacting differentiated cells with inhibitors of tyrosine phosphatases and apoptosis to de-differentiate differentiated cells into lineage restricted progenitor cells.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: March 2, 2021
    Assignee: The Regents of the University of California
    Inventors: Irina M. Conboy, Preeti Paliwal
  • Patent number: 10934351
    Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 2, 2021
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
  • Patent number: 10920225
    Abstract: This present invention discloses an antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene which is complementary to SEQ ID NO: 1. This antisense oligonucleotide can modulate alternative splicing site of mutant dopa decarboxylase gene. It is helpful to research and develop drug to treat AADC deficiency symptom. This present invention also discloses a method to use said antisense oligonucleotide in vitro.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 16, 2021
    Assignee: TAICHUNG VETERANS GENERAL HOSPITAL
    Inventors: Chi-Ren Tsai, Ching-Shiang Chi, Hsiu-Fen Lee
  • Patent number: 10851372
    Abstract: A method for preparing exosomes or exosome-like vesicles packaged with a nucleic acid of interest is provided. In certain embodiments, the method may comprise: introducing into an exosome-producing cell a nucleic acid construct comprising the nucleic acid sequence of interest incorporated in a pre-miR-451 structural mimic, and allowing the cell to produce exosomes. Nucleic acid constructs, compositions, and uses thereof are also provided.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 1, 2020
    Assignee: University of Ottawa
    Inventors: Derrick Gibbings, James Andrew Taylor
  • Patent number: 10801017
    Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 13, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Le Cong, Sam Locascio
  • Patent number: 10787667
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: September 29, 2020
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Patent number: 10774121
    Abstract: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Nazneen Dewji, S. Jonathan Singer
  • Patent number: 10767161
    Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: September 8, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mervin C. Yoder, David A. Ingram
  • Patent number: 10745671
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 18, 2020
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 10731155
    Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: August 4, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
  • Patent number: 10709818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 14, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10676744
    Abstract: MicroRNA-30 is identified as being dysregulated in adipose tissue macrophages during obesity and can be used in treatment of disease in which adipose tissue macrophage polarization dysregulation plays a part. Increased concentration of microRNA-30, e.g., via pharmaceutical delivery, can decrease the polarization of macrophages, and in particular adipose tissue macrophages, to inflammatory M1 phenotype and can decrease expression of pro-inflammatory cytokines. One or more members of the miR-30 family can be utilized in the methods. Methods can be beneficial in treatment of a large number of inflammatory diseases including obesity, diabetes, cancer, autoimmune, etc.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 9, 2020
    Assignee: University of South Carolina
    Inventors: Kathryn Miranda, Prakash Nagarkatti, Mitzi Nagarkatti
  • Patent number: 10676534
    Abstract: The invention relates to compositions of vault complexes for use as delivery agents for hydrophobic and/or aqueous insoluble therapeutic compounds. In one aspect, provided herein is a vault complex comprising a modified major vault protein (MVP), wherein the modified major vault protein comprises a fusion peptide, wherein said fusion peptide is fused to the N-terminus of the major vault protein, and wherein said peptide provides enhanced sequestering of a hydrophobic and/or aqueous insoluble therapeutic compound within the vault complex.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 9, 2020
    Assignee: The Regents of the University of California
    Inventors: Leonard H. Rome, Daniel Buehler, Heather D. Maynard
  • Patent number: 10619133
    Abstract: The present invention relates generally to the field of tissue engineering and in particular to the production of tissue films or cell matrices, which can be used as a living tissue substitute or an artificial tissue construct in tissue repair or replacement.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 14, 2020
    Assignee: NATIONAL UNIVERSITY OF IRELAND, GALWAY
    Inventors: Dimitrios Zeugolis, Abhigyan Satyam
  • Patent number: 10597654
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2991+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 24, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—CHIMIE PARIS TECH—ECOLE NATIONALE SUPERIEURE DE DE CHIME DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Patent number: 10588919
    Abstract: The invention provides a method of treating a vascular condition within a subject comprising administering a therapeutic agent to said subject that is capable of modulating the expression levels of a long non-coding RNA (IncRNA) selected from the group consisting of lncRNA2, lncRNA4, lncRNA5, lncRNA6, ncRNA7 and ncRNA8 as defined in FIG. 39.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 17, 2020
    Assignee: The University Court of the University of Edinburgh
    Inventors: Andy Baker, Margaret Dickson Ballantyne
  • Patent number: 10590391
    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: March 17, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Anthony Atala, James J. Yoo
  • Patent number: 10590418
    Abstract: Methods and compositions are provided for modulating, e.g., reducing, viral coding sequence expression in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 17, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Anton McCaffrey
  • Patent number: 10584335
    Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 10, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 10561716
    Abstract: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: February 18, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Douglas G. McNeel, Brian M. Olson
  • Patent number: 10557136
    Abstract: This invention provides a method for the in vivo delivery of oligonucleotides. The invention utilizes the presence of one or plurality of HES linked to an oligonucleotide to deliver a nucleic acid sequence of interest into the cytoplasm of cells and tissues of live organisms. The delivery vehicle is nontoxic to cells and organisms. Since delivery is sequence-independent and crosses membranes in a receptor-independent manner, the delivered oligonucleotide can target complementary sequences in the cytoplasm as well as in the nucleus of live cells. Sequences of bacterial or viral origin can also be targeted. The method can be used for delivery of genes coding for expression of specific proteins, antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs or any nucleic acid sequence in a living organism. The latter include mammals, plants, and microorganisms such as bacteria, protozoa, and viruses.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: February 11, 2020
    Assignee: Oncolmmunin Inc.
    Inventors: Beverly Packard, Akira Komoriya
  • Patent number: 10550387
    Abstract: Provided are a therapeutic and/or prophylactic agent for a lung disease and a method for screening for the therapeutic and/or prophylactic agent. Provided are a therapeutic and/or prophylactic agent for a lung disease comprising an Arid5A inhibitor as an active ingredient and a method for screening for the therapeutic and/or prophylactic agent.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 4, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tadamitsu Kishimoto, Kazuya Masuda
  • Patent number: 10526317
    Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 7, 2020
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
  • Patent number: 10527613
    Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: January 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dolly B. Tyan, Ge Chen
  • Patent number: 10512607
    Abstract: Embodiments of the present disclosure include particles, methods of making particles, methods of delivering an active agent using the particle, and the like.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 24, 2019
    Assignees: Vanderbilt University, University of Florida Research Foundation, Inc.
    Inventors: Benjamin G. Keselowsky, Jamal Lewis, Lawrence Premasiri Fernando, Craig L. Duvall, Brian C. Evans, Lirong Yang
  • Patent number: 10510143
    Abstract: Systems and methods for generating a mask for automated assessment of embryo quality are disclosed herein. The method for generating a mask for automated assessment of embryo quality can include receiving an image, including a plurality of pixels, of a human embryo from an imaging system. A pixel can be selected and features of the selected pixel can be determined by generating a plurality of random boxes of random sizes and at random locations about the selected pixel. The selected pixel can be identified as one of: inside of a mask area; and outside of the mask area based on the determined features.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Ares Trading S.A.
    Inventors: Yan Zhou, Martin T. Chian, Lei Tan, Daniel E. Koppel
  • Patent number: 10435690
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 8, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Gang Shen
  • Patent number: RE48887
    Abstract: This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-?, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: January 11, 2022
    Assignee: NITTO DENKO CORPORATION
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Bharat Majeti, Li Wang, Jihua Liu, Roger Adami, Wenbin Ying